Neuland Laboratories Ltd. (NEULANDLAB) Price & Analysis

Compare

4 Followers

NEULANDLAB Stock Chart & Stats

₹15265.60

₹591.15(4.14%)

At close: Jan 08 4:00 PM EST

₹15265.60

₹591.15(4.14%)

Day’s Range― - ―

52-Week Range₹10,060.00 - ₹19,748.40

Previous CloseN/A

Volume58.52K

Average Volume (3M)2.41K

Market Cap

₹171.49B

Enterprise Value₹171.64B

Total Cash (Recent Filing)₹2.40B

Total Debt (Recent Filing)₹0.00

Price to Earnings (P/E)95.7

Beta0.93

Next Earnings

May 12, 2026

EPS Estimate

75.16

Next Dividend Ex-DateN/A

Dividend Yield0.08%

Share Statistics

EPS (TTM)37.00

Shares Outstanding12,829,889

10 Day Avg. Volume1,318

30 Day Avg. Volume2,408

Financial Highlights & Ratios

PEG Ratio-4.25

Price to Book (P/B)9.66

Price to Sales (P/S)9.98

P/FCF Ratio132.83

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)246.06

Revenue Forecast (FY)₹18.49B

Bulls Say, Bears Say

Bulls Say

Revenue And Margin ImprovementA multi-year revenue uptrend with improving gross margins indicates durable demand for Neuland's APIs and better cost control. Sustained top-line growth and margin expansion support reinvestment into capacity and R&D, improving long-term competitiveness in specialty and generic APIs.

Balance Sheet StrengthA high equity ratio and generally prudent leverage give Neuland financial flexibility to fund capital-intensive API scale-ups and CMS projects. Strong asset backing reduces liquidity risk and enables the firm to bid for multi-year supply contracts without immediate refinancing pressure.

Operating Cash GenerationReliable operating cash flow and improved free cash flow since 2020 demonstrate the company's ability to convert earnings into spendable cash. This underpins sustainable capex, working capital needs and contract fulfilment for long-duration CMS engagements.

Bears Say

Rising Debt LevelsA rising debt stock, even with a healthy equity base, raises long-term financing and interest risks. If growth projects or CMS ramp-ups underperform, higher leverage can pressure cash flow available for operations and reduce flexibility for new strategic investments.

Variable Free Cash FlowFluctuating free cash flow creates uncertainty in the company’s capacity to self-fund capex and working capital for long commercial-scale projects. Repeated declines could force external financing, raising costs or constraining expansion into higher-margin custom manufacturing work.

Profitability Volatility And EPS DeclineInconsistent net margins and a sharp EPS contraction signal earnings quality and operational volatility. For a contract and API manufacturer, such swings can reflect pricing pressure, mix shifts or execution issues, undermining steady cash available for reinvestment and long-term planning.

Neuland Laboratories Ltd. News

Neuland Laboratories Opens Special Window for Re-lodgement of Physical Share Transfers

An announcement from Neuland Laboratories Ltd. ( ($IN:NEULANDLAB) ) is now available. Neuland Laboratories Ltd. has notified the...

2M ago

Neuland Laboratories Schedules Q2 FY26 Earnings Call

Neuland Laboratories Ltd. ( ($IN:NEULANDLAB) ) just unveiled an update. Neuland Laboratories Limited has scheduled an earnings call...

4M ago

Neuland Laboratories Opens Special Window for Share Transfer Requests

Neuland Laboratories Ltd. ( ($IN:NEULANDLAB) ) just unveiled an announcement. Neuland Laboratories Limited has announced a special window...

4M ago

Neuland Laboratories Announces Executive Restructuring via Postal Ballot

An announcement from Neuland Laboratories Ltd. ( ($IN:NEULANDLAB) ) is now available. Neuland Laboratories Ltd. has announced a...

5M ago

Neuland Laboratories Issues Corrigendum to Postal Ballot Notice

Neuland Laboratories Ltd. ( ($IN:NEULANDLAB) ) has issued an announcement. Neuland Laboratories Limited has announced a newspaper advertisement...

5M ago

Neuland Laboratories Opens Special Window for Physical Share Transfers

Neuland Laboratories Ltd. ( ($IN:NEULANDLAB) ) has issued an announcement. Neuland Laboratories Ltd. has announced a special window...

6M ago

NEULANDLAB FAQ

What was Neuland Laboratories Ltd.’s price range in the past 12 months?

Neuland Laboratories Ltd. lowest stock price was ₹10060.00 and its highest was ₹19748.40 in the past 12 months.

What is Neuland Laboratories Ltd.’s market cap?

Neuland Laboratories Ltd.’s market cap is ₹171.49B.

When is Neuland Laboratories Ltd.’s upcoming earnings report date?

Neuland Laboratories Ltd.’s upcoming earnings report date is May 12, 2026 which is in 74 days.

How were Neuland Laboratories Ltd.’s earnings last quarter?

Neuland Laboratories Ltd. released its earnings results on Feb 09, 2026. The company reported ₹37 earnings per share for the quarter, missing the consensus estimate of ₹56.52 by -₹19.52.

Is Neuland Laboratories Ltd. overvalued?

According to Wall Street analysts Neuland Laboratories Ltd.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Neuland Laboratories Ltd. pay dividends?

Neuland Laboratories Ltd. pays a Annually dividend of ₹12 which represents an annual dividend yield of 0.08%. See more information on Neuland Laboratories Ltd. dividends here

What is Neuland Laboratories Ltd.’s EPS estimate?

Neuland Laboratories Ltd.’s EPS estimate is 75.16.

How many shares outstanding does Neuland Laboratories Ltd. have?

Neuland Laboratories Ltd. has 12,829,889 shares outstanding.

What happened to Neuland Laboratories Ltd.’s price movement after its last earnings report?

Neuland Laboratories Ltd. reported an EPS of ₹37 in its last earnings report, missing expectations of ₹56.52. Following the earnings report the stock price went up 6.856%.

Which hedge fund is a major shareholder of Neuland Laboratories Ltd.?

Currently, no hedge funds are holding shares in IN:NEULANDLAB

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Neuland Laboratories Ltd.

Neuland Laboratories Limited manufactures and sells active pharmaceutical ingredients (APIs) in India, Europe, the United States, and internationally. The company's APIs are used in various therapeutic areas, including antiasthmatics, cardiovasculars, antifungal, anticonvulsants, central nervous system, fluoroquinolones, antipsychotic, antibacterial, and anti-parkinson. It also provides custom manufacturing solutions, as well as peptide synthesis services. The company was incorporated in 1984 and is headquartered in Hyderabad, India.